rs114577328 - POLR1HASP
Magnitude 4.5 · 1 study on file
Reported associations
-
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study - Unknown journal (n.d.) · Unknown authors · PubMed 28043905
ABSTRACT: BACKGROUND & AIMS We performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury (DILI) from licensed drugs without previously reported genetic risk factors. METHODS We performed a GWAS of 862 persons with DILI and 10588 population-matched controls. The first set of cases was recruited prior to May 2009 in Europe (n=137) or the USA (n=274). The second set of cases were identified from May 2009 through May 2013 from international collaborative studies performed in Europe, the USA and South America. For the GWAS, we included only cases of European ancestry associated with a particular drug (but not flucloxacillin or amoxicillin-clavulanate). We used DNA samples from all subjects to analyze human leukocyte antigen (HLA) genes and s
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
HLA-A*33:01 DILI risk and high-risk medication list High
HLA-A*33:01 (rs114577328) increases idiosyncratic drug-induced liver injury risk 40-163 fold for terbinafine, ticlopidine, fenofibrate, methyldopa, enalapril, sertraline, and erythromycin.
Share genetic result with all prescribers; discuss safer medication alternatives before starting any new drug.
Screening
-
Baseline liver function testing Moderate
Establishes normal baseline values and enables early detection of hepatocellular vs cholestatic injury patterns if DILI develops.
Obtain baseline AST, ALT, ALP, bilirubin before starting any medication with DILI association.